Clinical trials: Arbovirus Infections
Dengue, Arbovirus Infections
Improving Disease Prevention Strategies by Integrating Socio-spatial Characterization of Human Mobility
In contrast to the trend expected based on existing prediction models, dengue incidence was historically low during the pandemic mobility restrictions of 2020-2021 in most dengue endemic countries.
- Conditions
- Dengue, Arbovirus Infections, Epidemic Disease, Behavior, Health
- Trial name
- DI-MOB (NCT06599970)
- Testing
- No intervention
- Where
- Cuba
- Volunteers
- 810 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Dengue, Severe Dengue
Therapeutics for Moderate and Severe Dengue
The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection.
- Conditions
- Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases
- Trial name
- DEN-HOST (NCT07543458)
- Testing
- Dexamethasone, N-Acetylcysteine, Standard of care
- Where
- 18 sites in Bangladesh, Brazil and 8 more
- Volunteers
- 8,800 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Arbovirus Infections
ARBOspot: Characterization of Arbovirus Specific T Cell Response in Patients by Using Enzyme Linked Immunospot (ELISpot) Assays
Arboviruses (arthropod-borne viruses), are a group of RNA viruses that are transmitted to vertebrate hosts by hematophagous arthropods like mosquitos, ticks, and sandflies.
- Trial name
- ARBOspot (NCT07291206)
- Testing
- Immunological assays for charactarization of T-cell mediated response, Immunological assays
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
HIV Infection, HBV Infection
"Pregnancy and Viral Infections: Impact on Pregnant Women and Their Children. French Prospective Cohort"
The VIROPREG study is a French prospective multicenter cohort study that aims to assess the impact of viral infections and antiviral treatments received during pregnancy on maternal and child health.
- Conditions
- HIV Infection, HBV Infection, HDV Infection, HCV Infection
- Trial name
- VIROPREG (NCT07412977)
- Testing
- Blood sampling, Umbilical cord blood sampling, Survey using a questionnaire
- Where
- France
- Volunteers
- 5,160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Arbovirus Infections, Respiratory Infection Virus
Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.
Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of…
- Trial name
- AEVI-Fiji (NCT07229677)
- Where
- Fiji
- Volunteers
- 910 people, healthy volunteers welcome
- Sponsor
- Fiji National University
Arbovirus Infections
Spatial Repellents for Aedes-borne Virus Control in Sri Lanka
The primary objective of the study is to demonstrate and quantify the protective efficacy (PE) of a single SR product, in reducing DENV infection and active Aedes-borne virus (ABV) disease in human cohorts.
- Trial name
- AEGIS ABV (NCT05452447)
- Testing
- Transfluthrin
- Where
- 2 sites in Sri Lanka
- Volunteers
- 6,949 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Arbovirus Infections, Zika
Virological and Immunological Determinants of Arbovirus Infection in New Caledonia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, particularly in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Zika, Dengue, Chikungunya
- Trial name
- VIRIMA (NCT04619823)
- Testing
- Blood sample collection
- Where
- New Caledonia
- Volunteers
- 250 people
- Sponsor
- Institut Pasteur
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue, Vector Borne Diseases
Sustainable Reduction of Dengue in Colombia: Vector Breeding Site Intervention With an Insecticidal Coating
Effective control of Aedes aegypti mosquitoes in breeding sites with high reproductive rates could have a major impact on reducing arbovirosis in endemic communities.
- Conditions
- Dengue, Vector Borne Diseases, Arbovirus Infections, Zika
- Trial name
- NCT06268691
- Testing
- Insecticide Coating INESFLY
- Where
- 2 sites in Colombia, Germany
- Volunteers
- 35,000 people, healthy volunteers welcome
- Sponsor
- Rocio Cardenas Sanchez
Viral Infection
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
The objective is to evaluate the safety and tolerability of a single-ascending oral dose of UV-4B in healthy subjects and to determine pharmacokinetic parameters describing absorption and elimination following a single dose of…
- Trial name
- UV (NCT02061358)
- Testing
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Viral Infection
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
- Trial name
- NCT02696291
- Testing
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine, Inactivated
This study is designed to determine the safety and immunogenicity of an inactivated Rift Valley Fever (RVF) Vaccine in adults
- Trial name
- RVF (NCT00869713)
- Testing
- Inactivated, Dried (TSI-GSD 200), RVF Vaccine
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Arbovirus Infections
World Mosquito Program Noumea - Human Sample Component
The dengue, Zika and chikungunya arboviruses represent potentially severe infections to which the New Caledonian population is exposed.
- Trial name
- NCT03552094
- Testing
- Blood donations of hemochromatosis or polycythemia patients, Blood donations of healthy donors
- Where
- France
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Arbovirus Infections, SARS-CoV Infection
Human Epidemiology of Newly Identified Arboviruses
A local network is being set up to study the impact of arboviruses in our region. It is committed to a one-health approach, in particular with research without a priori for new viruses hosted among vectors and wildlife.
- Trial name
- ARBODOCC (NCT04954352)
- Where
- France
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Arbovirus Infections
Spatial Repellents for Arbovirus Control
Dengue viruses are the most medically important arthropod-borne pathogens worldwide, with transmission occurring in most tropical and sub-tropical regions. An estimated 390 million infections occur yearly.
- Trial name
- NCT03553277
- Testing
- transfluthrin
- Where
- Peru
- Volunteers
- 18,240 people, healthy volunteers welcome
- Sponsor
- University of Notre Dame
Arbovirus Infections
Sero-epidemiology of Priority Arboviruses in French Guiana
Dengue is an important public health problem despite the efforts of local health authorities to mitigate the impact of epidemics and the epidemiology of dengue evolved from an endemo-epidemic to a hyper-endemic state.
- Trial name
- EPI-ARBO (NCT03210363)
- Testing
- Human Biological samples
- Where
- France
- Volunteers
- 2,697 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Encephalitis, Myelitis
Neurologic Manifestations of the Arbovirus Infection in Colombia
This is a multi-center case-control study that aims to define the association between the exposure to an arbovirus infection and the development of a neurological syndrome in patients from Colombia.
- Conditions
- Encephalitis, Myelitis, Guillain-Barre Syndrome, Cranial Nerve Palsies
- Trial name
- NCT03206541
- Where
- 8 sites in Colombia
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Rift Valley Fever
Safety and Immunogenicity Study of Rift Valley Fever Vaccine
This study is designed to determine the safety and immunogenicity of a Rift Valley Fever (RVF) Vaccine
- Trial name
- RVF (NCT00584194)
- Testing
- TSI-GSD 200 RVF Vaccine
- Where
- United States
- Volunteers
- 278 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command